Clinical Trial Update: ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial update for ABI-008 in hormone-refractory prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ABI-008

Snippet

Sponsor: Celgene | Conditions: Hormone Refractory Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED